The cholesterol 24-hydroxylase activates autophagy and decreases mutant huntingtin build-up in a neuroblastoma culture model of Huntington’s disease

[1]  J. Caboche,et al.  CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease. , 2019, Brain : a journal of neurology.

[2]  Carlos A. Matos,et al.  Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia , 2019, Acta Neuropathologica.

[3]  S. Tabrizi,et al.  Huntingtin Lowering Strategies for Disease Modification in Huntington’s Disease , 2019, Neuron.

[4]  Carlos A. Matos,et al.  Machado–Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy , 2018, Journal of neurochemistry.

[5]  Carlos A. Matos,et al.  Cordycepin activates autophagy through AMPK phosphorylation to reduce abnormalities in Machado‐Joseph disease models , 2018, Human molecular genetics.

[6]  A. Brice,et al.  Deregulation of autophagy in postmortem brains of Machado‐Joseph disease patients , 2018, Neuropathology : official journal of the Japanese Society of Neuropathology.

[7]  Lidia Gaffke,et al.  Correction of Huntington’s Disease Phenotype by Genistein-Induced Autophagy in the Cellular Model , 2018, NeuroMolecular Medicine.

[8]  P. McColgan,et al.  Huntington's disease: a clinical review , 2018, European journal of neurology.

[9]  I. Bièche,et al.  Neuronal Cholesterol Accumulation Induced by Cyp46a1 Down-Regulation in Mouse Hippocampus Disrupts Brain Lipid Homeostasis , 2017, Front. Mol. Neurosci..

[10]  E. Hol,et al.  Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell‐type‐specific , 2016, Glia.

[11]  C. Pagès,et al.  CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease , 2016, Brain : a journal of neurology.

[12]  A. Vercelli,et al.  Cholesterol‐loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice , 2015, EMBO molecular medicine.

[13]  H. Hirai,et al.  Re-establishing ataxin-2 downregulates translation of mutant ataxin-3 and alleviates Machado-Joseph disease. , 2015, Brain : a journal of neurology.

[14]  R. Miles,et al.  CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. , 2015, Brain : a journal of neurology.

[15]  D. Ehrnhoefer,et al.  Autophagy in Huntington disease and huntingtin in autophagy , 2015, Trends in Neurosciences.

[16]  F. Pfrieger,et al.  Cholesterol in brain disease: sometimes determinant and frequently implicated , 2014, EMBO reports.

[17]  V. Fung,et al.  An update on Huntington's disease: from the gene to the clinic. , 2014, Current opinion in neurology.

[18]  M. Priault,et al.  The autophagy/lysosome pathway is impaired in SCA7 patients and SCA7 knock-in mice , 2014, Acta Neuropathologica.

[19]  Jane S. Paulsen,et al.  Huntington disease: natural history, biomarkers and prospects for therapeutics , 2014, Nature Reviews Neurology.

[20]  N. Déglon,et al.  Overexpression of Mutant Ataxin-3 in Mouse Cerebellum Induces Ataxia and Cerebellar Neuropathology , 2013, The Cerebellum.

[21]  H. Hirai,et al.  Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease. , 2013, Brain : a journal of neurology.

[22]  J. Vance.  Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases , 2012, Disease Models & Mechanisms.

[23]  J. Son,et al.  Neuronal autophagy and neurodegenerative diseases , 2012, Experimental & Molecular Medicine.

[24]  P. V. Van Veldhoven,et al.  Regulation of tyrosine kinase B activity by the Cyp46/cholesterol loss pathway in mature hippocampal neurons: relevance for neuronal survival under stress and in aging , 2011, Journal of neurochemistry.

[25]  R. Roos,et al.  Huntington's disease: a clinical review , 2010, Orphanet journal of rare diseases.

[26]  M. MacDonald,et al.  Cholesterol Defect Is Marked across Multiple Rodent Models of Huntington's Disease and Is Manifest in Astrocytes , 2010, The Journal of Neuroscience.

[27]  D. Russell,et al.  Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. , 2009, Annual review of biochemistry.

[28]  A. Smit,et al.  SREBPs: SREBP function in glia–neuron interactions , 2009, The FEBS journal.

[29]  A. Kenworthy,et al.  Lipid rafts, cholesterol, and the brain , 2008, Neuropharmacology.

[30]  D. Rubinsztein,et al.  Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. , 2008, Nature chemical biology.

[31]  S. Andersson,et al.  Neuronal expression and subcellular localization of cholesterol 24‐hydroxylase in the mouse brain , 2008, The Journal of comparative neurology.

[32]  D. Rubinsztein,et al.  A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. , 2008, Human molecular genetics.

[33]  C. Mariotti,et al.  Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington’s disease , 2007, Neurobiology of Disease.

[34]  M. Hayden,et al.  Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. , 2007, Human molecular genetics.

[35]  T. Noda,et al.  Dissection of the Autophagosome Maturation Process by a Novel Reporter Protein, Tandem Fluorescent-Tagged LC3 , 2007, Autophagy.

[36]  I. Björkhem,et al.  Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain , 2006, Journal of internal medicine.

[37]  Anne E Carpenter,et al.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.

[38]  J. Olson,et al.  Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease , 2005, The Journal of Neuroscience.

[39]  Steve Meaney,et al.  Brain Cholesterol: Long Secret Life Behind a Barrier , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[40]  Wilhelm Gaus,et al.  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2004, Neurology.

[41]  N Makris,et al.  Evidence for more widespread cerebral pathology in early HD , 2003, Neurology.

[42]  J. Dietschy,et al.  Control of Cholesterol Turnover in the Mouse* , 2002, The Journal of Biological Chemistry.

[43]  D. Rubinsztein,et al.  A molecular investigation of true dominance in Huntington’s disease , 1999, Journal of medical genetics.

[44]  J M Guileyardo,et al.  cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Wahren,et al.  Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. , 1998, Journal of lipid research.

[46]  A E Rosser,et al.  Evidence for specific cognitive deficits in preclinical Huntington's disease. , 1998, Brain : a journal of neurology.

[47]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[48]  Pierre Bougnères,et al.  Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  V. Hachinski,et al.  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Authors' reply , 2004 .

[50]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[51]  D. Lütjohann,et al.  Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study. , 2001, Journal of lipid research.

[52]  H. Zoghbi,et al.  Glutamine repeats and neurodegeneration. , 2000, Annual review of neuroscience.